Arguably the most well-known SERD is AstraZeneca’s Faslodex, which was approved in 2002 for breast cancer and is administered ...

Imlifidase, an IgG-destroying enzyme, could receive FDA approval in the second half of 2026 and hit peak sales of $306 ...

Ladenburg, Germany–based Heidelberg Pharma is laying off approximately 75% of its workforce in a bid to extend its cash ...

Though details remain scant, the pending order is expected to be the latest effort in President Donald Trump's campaign to ...

MapLight Therapeutics, the second biotech to launch a Nasdaq bid this month, is a neuro-focused company advancing treatments ...

The agency also pointed to the use of Tylenol and other acetaminophen products during pregnancy as being potentially linked ...

Companies that have broken ground on or are actively constructing manufacturing facilities in the U.S. are exempted from the ...

The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with ...

Truist analysts called the results "encouraging" while pointing out certain unknowns in the data. Immuneering plans to kick ...

With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space ...

Three draft recommendation documents published on Wednesday are intended to guide drug sponsors and accelerate the ...

The decision to stop the Phase IIb study was driven by “strategic business reasons,” according to a federal clinical trials ...